Loss of Parafibromin Immunoreactivity Is a Distinguishing Feature of Parathyroid Carcinoma
暂无分享,去创建一个
Ximing J. Yang | K. Soo | C. Morrison | B. Teh | M. Tretiakova | J. Resau | M. Tan | C. Haven | P. Zhao | W. Cheah | J. Burgess | H. Morreau | Pengfei Wang | B. Cao | Chun Zhang | Eeva Korpi-Hyovalti | Brian B Cao | Pengfei Wang
[1] K. Sandelin,et al. Prognostic factors in parathyroid cancer: A review of 95 cases , 1992, World Journal of Surgery.
[2] G. Clayman,et al. Parathyroid carcinoma: Evaluation and interdisciplinary management , 2004, Cancer.
[3] G. Fleuren,et al. Differential expression of the calcium sensing receptor and combined loss of chromosomes 1q and 11q in parathyroid carcinoma , 2004, The Journal of pathology.
[4] C. Marcocci,et al. A reappraisal of the Rb1 gene abnormalities in the diagnosis of parathyroid cancer , 2004, Clinical endocrinology.
[5] K. Sandelin,et al. Clinical course of metastatic parathyroid cancer , 1994, World Journal of Surgery.
[6] J. Carpten,et al. Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma. , 2003, The New England journal of medicine.
[7] W. Simonds,et al. HRPT2, a marker of parathyroid cancer. , 2003, The New England journal of medicine.
[8] K Hammje,et al. HRPT2 mutations are associated with malignancy in sporadic parathyroid tumours , 2003, Journal of medical genetics.
[9] N. Palanisamy,et al. Mutational analyses of RB and BRCA2 as candidate tumour suppressor genes in parathyroid carcinoma , 2003, Clinical endocrinology.
[10] C. Cordon-Cardo,et al. Parathyroid neoplasms: clinical, histopathological, and tissue microarray-based molecular analysis. , 2003, Human pathology.
[11] J. Carpten,et al. HRPT2, encoding parafibromin, is mutated in hyperparathyroidism–jaw tumor syndrome , 2002, Nature Genetics.
[12] S. Wells,et al. Recurrent or persistent hyperparathyroidism. , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[13] F. Collins,et al. Hyperparathyroidism in hereditary syndromes: special expressions and special managements. , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[14] L. Memeo,et al. Concurrent parathyroid adenomas and carcinoma in the setting of multiple endocrine neoplasia type 1: presentation as hypercalcemic crisis. , 2002, Mayo Clinic proceedings.
[15] M. Papotti,et al. Oxyphil Parathyroid Carcinomas: A Clinicopathologic and Immunohistochemical Study of 10 Cases , 2002, The American journal of surgical pathology.
[16] Amos Bairoch,et al. ScanProsite: a reference implementation of a PROSITE scanning tool. , 2002, Applied bioinformatics.
[17] M. Sarbia,et al. Parathyroid carcinoma: problems in diagnosis and the need for radical surgery even in recurrent disease. , 2001, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[18] E. Shane,et al. CHAPTER 33 – Parathyroid Carcinoma , 2001 .
[19] C. Larsson,et al. Patterns of chromosomal imbalances in parathyroid carcinomas. , 2000, The American journal of pathology.
[20] S. Aviel-Ronen,et al. Brown tumour of hyperparathyroidism in the mandible associated with atypical parathyroid adenoma. , 2000, The Journal of laryngology and otology.
[21] C. Larsson,et al. A genotypic and histopathological study of a large Dutch kindred with hyperparathyroidism-jaw tumor syndrome. , 2000, The Journal of clinical endocrinology and metabolism.
[22] I. Fleming,et al. Two hundred eighty‐six cases of parathyroid carcinoma treated in the U.S. between 1985–1995 , 1999, Cancer.
[23] J. Nährig,et al. Protocol for ultrarapid immunostaining of frozen sections. , 1999, Journal of clinical pathology.
[24] P. Wollan,et al. Parathyroid hyperplasia, adenomas, and carcinomas: differential expression of p27Kip1 protein. , 1999, The American journal of surgical pathology.
[25] C. Larsson,et al. Evaluation of Retinoblastoma and Ki-67 Immunostaining as Diagnostic Markers of Benign and Malignant Parathyroid Disease , 1999, World Journal of Surgery.
[26] D. D’amico,et al. Parathyroid Carcinoma: Sixteen New Cases and Suggestions for Correct Management , 1998, World Journal of Surgery.
[27] J. Kononen,et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens , 1998, Nature Medicine.
[28] R. Newcombe. Two-sided confidence intervals for the single proportion: comparison of seven methods. , 1998, Statistics in medicine.
[29] T. Oyama,et al. Cytologic characteristics of parathyroid carcinoma: A case report , 1998, Diagnostic cytopathology.
[30] C. Marcocci,et al. Bcl-2, p53 and MIB-1 expression in normal and neoplastic parathyroid tissues , 1998, Journal of endocrinological investigation.
[31] K. Yoshimoto,et al. Familial isolated primary hyperparathyroidism with parathyroid carcinomas: clinical and molecular features , 1998, Clinical endocrinology.
[32] T. Obara,et al. Functioning parathyroid carcinoma: clinicopathologic features and rational treatment. , 1997, Seminars in surgical oncology.
[33] L. Grimelius,et al. Pathology of parathyroid tumors. , 1997, Seminars in surgical oncology.
[34] C. Chang,et al. Cdc73p and Paf1p are found in a novel RNA polymerase II-containing complex distinct from the Srbp-containing holoenzyme , 1997, Molecular and cellular biology.
[35] M. Merino,et al. The role of prognostic markers (MiB-1, RB, and bcl-2) in the diagnosis of parathyroid tumors. , 1997, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.
[36] C. Larsson,et al. Allelic loss of the retinoblastoma tumor suppressor gene: a marker for aggressive parathyroid tumors? , 1996, The Journal of clinical endocrinology and metabolism.
[37] M. Sheppard,et al. Loss of heterozygosity studies at the retinoblastoma and breast cancer susceptibility (BRCA2) loci in pituitary, parathyroid, pancreatic and carcinoid tumours , 1996, Clinical endocrinology.
[38] P. Wollan,et al. Immunohistochemical analysis of the cell cycle-associated antigens Ki-67 and retinoblastoma protein in parathyroid carcinomas and adenomas , 1995, Endocrine pathology.
[39] A. Thor,et al. Loss of the retinoblastoma tumor-suppressor gene in parathyroid carcinoma. , 1994, The New England journal of medicine.
[40] G. Guyatt,et al. Users' Guides to the Medical Literature: III. How to Use an Article About a Diagnostic Test: B. What Are the Results and Will They Help Me In Caring for My Patients? , 1994 .
[41] G. Guyatt,et al. Users' guides to the medical literature. III. How to use an article about a diagnostic test. B. What are the results and will they help me in caring for my patients? The Evidence-Based Medicine Working Group. , 1994, JAMA.
[42] K. Sandelin,et al. Histopathological Variables and DNA Cytometry in Parathyroid Carcinoma , 1993, The American journal of surgical pathology.
[43] August Da,et al. Parathyroid carcinoma: The relationship of nuclear DNA content to clinical outcome , 1993 .
[44] C. B. Bagwell,et al. Parathyroid carcinoma: the relationship of nuclear DNA content to clinical outcome. , 1993, Surgery.
[45] G. Guyatt,et al. Users' guides to the medical literature. , 1993, JAMA.
[46] R. Norum,et al. Hereditary hyperparathyroidism and multiple ossifying jaw fibromas: a clinically and genetically distinct syndrome. , 1990, Surgery.
[47] Y. Fujimoto,et al. Flow cytometric DNA analysis of parathyroid tumors. Implication of aneuploidy for pathologic and biologic classification , 1990, Cancer.
[48] J. Taxy,et al. The intrathyroidal hyperfunctioning parathyroid gland. , 1989, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.
[49] K. Chew,et al. Deoxyribonucleic acid cytometry helps identify parathyroid carcinomas. , 1988, The Journal of clinical endocrinology and metabolism.
[50] O. Clark,et al. Parathyroid carcinoma versus parathyroid adenoma in patients with profound hypercalcemia. , 1987, Surgery.
[51] B. Castleman,et al. Parathyroid carcinoma. A study of 70 cases , 1973, Cancer.